


Switching on a Signaling Pathway with an Organoruthenium Complex**

Douglas S. Williams, G. Ekin Atilla, Howard Bregman, Arpine Arzoumanian, Peter S. Klein, and Eric Meggers*

Altering cellular function with small synthetic molecules is a general approach for the design of drugs (medicinal chemistry) and molecular probes (chemical genetics). Medicinal chemistry and chemical genetics are focused predominately on the design of organic molecules, whereas inorganic compounds find applications mainly for their reactivity (e.g., cisplatin as DNA-reactive therapeutic) or imaging properties (e.g., gadolinium complexes as MRI diagnostics).^[1,2] We are exploring a new direction that aims at utilizing the unique structural opportunities of metal complexes for the design of “organiclike” small-molecule probes and drugs.^[3,4] We recently described an organoruthenium compound to be a low-nanomolar inhibitor for the protein kinase glycogen synthase kinase 3 (GSK-3).^[4] Here we disclose our success in developing this compound into a molecular probe for cellular signal transduction pathways involving GSK-3.^[5]

Our strategy for the design of metal complexes as protein kinase inhibitors uses the class of indolocarbazole alkaloids (e.g., staurosporine) as a lead structure. Accordingly, these metal complexes bear a bidentate ligand which retains the structural features of the indolocarbazole heterocycle. This targets the metal complexes to the ATP-binding site by enabling two hydrogen bonds to the backbone of the hinge between the N-terminal and C-terminal kinase domains, analogous to ATP and conventional organic indolocarbazole inhibitors (Scheme 1).^[6] The remaining ligand sphere of the ruthenium atom gives the opportunity to create interactions with other parts of the ATP-binding site. Following this strategy, we recently described ruthenium compound **1-H** as a selective low-nanomolar and ATP-competitive inhibitor of GSK-3.^[4] The key component of the design was the novel pyridocarbazole ligand **2-H**, derived from arcylriaflavin A by just replacing one indole moiety with a pyridine residue.



Scheme 1. Designing ruthenium complexes as protein kinase inhibitors by mimicking ATP-competitive indolocarbazoles.

Here we introduce the ruthenium complex **1-OH** (Scheme 1), derived from **1-H** by adding a single hydroxy group to the indole moiety. Molecular modeling suggests that this OH group can occupy a small hydrophilic cavity within the ATP-binding site of GSK-3. Indeed, this modification not only increases the affinity for GSK-3 by an order of magnitude, but at the same time increases water solubility considerably, and thus makes it a promising molecular probe for GSK-3. GSK-3 is a component and negative regulator of the wnt signaling pathway, and we demonstrate in the following that **1-OH** can switch on the wnt signaling pathway by inhibiting GSK-3 inside living cells and in *Xenopus* embryos.

We devised a short and economic synthetic route to this class of metalated pyridocarbazoles (Scheme 2). Starting with aryl hydrazine hydrochloride **3**, Fischer indole synthesis and protecting-group exchange lead to pyridoindole **4**, which is deprotonated and treated with the TBS-protected dibromomaleimide **5** to yield monosubstitution product **6**. The key step of the synthetic scheme is the following smooth anaerobic photocyclization to the TBS-protected pyridocarbazole **7** in 78% yield.^[7] Compound **7** can be deprotected with TBAF to give **2-OH** or treated with [Ru(Cp)(CO)(CH₃CN)₂]₂PF₆ in the presence of K₂CO₃ to yield cyclometalated ruthenium complex **8**.^[8] Subsequent TBS deprotection with TBAF gives **1-OH**. Complex **1-OH** is stable in aqueous solution, in cell culture medium, under air, and can even withstand a 5 mM solution of 2-mercaptoethanol for 12 h without any sign of decomposition, as determined by ¹H NMR spectroscopy. Furthermore, **1-OH** also has favorable solubility in water. For example, it can be dissolved in 3% DMSO/water at a concentration of 1 mM.


We next examined the potency of **1-OH** by determining the concentration required for 50% inhibition (IC₅₀) of GSK-3α (the α isoform) and GSK-3β (the β isoform). The IC₅₀ of **1-OH** is 300 pM and 500 pM for GSK-3α and GSK-3β, respectively, approximately an order of magnitude lower than that

[*] D. S. Williams, G. E. Atilla, H. Bregman, Prof. Dr. E. Meggers
Department of Chemistry
University of Pennsylvania
231 South 34th Street, Philadelphia, PA 19104 (USA)
Fax: (+1) 215-746-0348
E-mail: meggers@sas.upenn.edu

A. Arzoumanian, Prof. Dr. P. S. Klein
Department of Medicine
Division of Hematology-Oncology and Howard Hughes Medical Institute
University of Pennsylvania
415 Curie Blvd, Philadelphia, PA 19104 (USA)

[**] We thank the University of Pennsylvania and the Camille and Henry Dreyfus Foundation for financial support of this research.

Supporting information for this article is available on the WWW under <http://www.angewandte.org> or from the author.



Scheme 2. Synthesis of ruthenium complex **1-OH** and pyridocarbazole **2-OH**. a) 2-Acetylpyridine, *t*BuOH, 4 h reflux (100%). b) Trimethylsilyl polyphosphate, 115 °C, overnight (63%). c) BF_3 , CH_2Cl_2 , -60 °C, then RT overnight (87%). d) DIEA, DMF, 0 °C, 40 min, then TBS triflate, 0 °C, 1 h (71%). e) Li hexamethyldisilazide, THF, -15 °C, 45 min, then **5** in THF, -15 °C, 15 min, then RT, 45 min (58%). f) *h* ν , Pyrex filter, MeCN, 3 h, (78%). g) $[\text{Ru}(\text{Cp})(\text{CH}_3\text{CN})_2(\text{CO})]\text{PF}_6$, K_2CO_3 , MeCN, 55 °C, overnight (86%). h) TBAF, CH_2Cl_2 , RT, 30 min (87%). i) TBAF, CH_2Cl_2 , RT, 30 min (80%). DIEA = *N,N*-diisopropylethylamine, TBAF = tetrabutylammonium fluoride, TBS = *tert*-butyldimethylsilyl.

of the initial complex **1-H**. For comparison, ruthenium compound **1-OH** is at least 100 times more potent against GSK-3 than staurosporine under our experimental conditions (IC_{50} of 40 nM against GSK-3 α).^[9–12] Methylation of the imide nitrogen atom (**Me1-OH**) reduces the activity dramatically by almost four orders of magnitude (IC_{50} of 2 μM against GSK-3 α), as demonstrated by the IC_{50} curves in Figure 1, which reconfirms that the potency of **1-OH** is entirely based on




Figure 1. IC_{50} curves with GSK-3 α obtained by phosphorylation of phosphoglycogen synthase peptide-2 with $[\gamma\text{-}^{32}\text{P}]\text{ATP}$: ruthenium complex **1-OH** (●), ligand **2-OH** (○), and methylated ruthenium complex **Me1-OH** (▼).

specific recognition. It is also noteworthy that ligand **2-OH** is almost two orders of magnitude less active than the corresponding ruthenium complex **1-OH**, clearly verifying that the entire assembly is necessary for full activity.

Ruthenium complex **1-OH** also shows high selectivity. The protein kinases Abl (IC_{50} = 1 μM), CHK-1 (IC_{50} = 2 μM), Lck (IC_{50} = 500 nM), MAPK-1 (IC_{50} > 3 μM), RSK-1 (25 nM), Src (IC_{50} = 4 μM), and Zap-70 (IC_{50} > 10 μM) are inhibited at concentrations that are 80 to more than 30000 times higher relative to GSK-3 α . Even the evolutionarily closely related protein kinase CDK-2 is only inhibited with an IC_{50} of 200 nM.^[9–12]

Next, we investigated whether **1-OH** can inhibit GSK-3 inside mammalian cells. GSK-3 is a negative regulator of the wnt signal transduction pathway that phosphorylates β -catenin.^[13] Phosphorylated β -catenin is unstable and is degraded rapidly by the proteasome. Wnt signaling inhibits GSK-3, leading to stabilization of β -catenin protein. β -Catenin then accumulates and serves as a transcriptional coactivator through its interaction with the T-cell factor (Tcf) family of transcription factors. Thus inhibition of GSK-3 by pharmacological inhibitors or by wnt signaling leads to increased β -catenin levels and activation of wnt-dependent transcription.

To test for cellular accumulation of β -catenin as a response to inhibition of GSK-3 by ruthenium complex **1-OH**, we used human embryonic kidney cells (HEK293T) that have stably incorporated a Tcf-luciferase transcription reporter (OT-Luc cells). This transcription reporter generates luciferase in response to increased concentrations of β -catenin.^[14] Exposure of OT-Luc cells to varying concentrations of **1-OH** over a period of 24 h yields a strong upregulation of luciferase in the concentration window of 3 μM down to 100 nM (Figure 2A). For example, at a **1-OH** concentration of 300 nM, luciferase activity is enhanced by a factor of 1180. Intriguingly, at the same time, methylated control **Me1-OH** and free ligand **2-OH** do not yield any significant increase in luciferase activity at a concentration of 1 μM (1.6- and 2.4-fold, respectively). As a positive control, the established selective GSK-3 inhibitor LiCl leads to an increase of the luminescence signal by a factor of 1190 at a concentration of 30 mM.^[14,15]

To verify the accumulation of β -catenin directly, we analyzed the cellular β -catenin concentration by Western blotting after incubation with **1-OH**. Figure 2B demonstrates an increase in β -catenin in the presence of **1-OH**, but not **Me1-OH** or **2-OH**, at 1 μM . These experiments demonstrate that ruthenium complex **1-OH** crosses the cell membrane and activates the wnt pathway at low micromolar and even nanomolar concentrations.

It is also noteworthy that **1-OH** does not show any signs of cytotoxicity at concentrations of 3 μM or less, supporting our assumption that the kinetically inert ruthenium center is only an innocent nonreactive bystander. The integrity of complex **1-OH** inside the cell is also reinforced by the fact that the entire ligand assembly is necessary for the activity inside the cell and that the free ligand **2-OH** does not activate the wnt pathway itself at similar concentrations. This is a remarkable observation considering the millimolar concentrations of

- [3] L. Zhang, P. J. Carroll, E. Meggers, *Org. Lett.* **2004**, *6*, 521–523.
- [4] H. Bregman, D. S. Williams, G. E. Atilla, P. J. Carroll, E. Meggers, *J. Am. Chem. Soc.* **2004**, *126*, 13594–13595.
- [5] For pioneering work on using chemically inert ruthenium complexes as bioactive compounds in vivo, see a) F. P. Dwyer, E. C. Gyarfas, W. P. Rogers, J. H. Koch, *Nature* **1952**, *170*, 190–191; b) F. P. Dwyer, E. C. Gyarfas, R. D. Wright, A. Shulman, *Nature* **1957**, *179*, 425–426.
- [6] a) L. M. Toledo, N. B. Lydon, *Structure* **1997**, *5*, 1551–1556; b) A. M. Lawrie, M. E. M. Noble, P. Tunnah, N. R. Brown, L. N. Johnson, J. A. Endicott, *Nat. Struct. Biol.* **1997**, *4*, 796–801.
- [7] A related approach was used to synthesize granulatinimides: a) T. Yoshida, M. Nishiyachi, N. Nakashima, M. Murase, E. Kotani, *Chem. Pharm. Bull.* **2002**, *50*, 872–876; b) T. Yoshida, M. Nishiyachi, N. Nakashima, M. Murase, E. Kotani, *Chem. Pharm. Bull.* **2003**, *51*, 209–214.
- [8] A related cyclometalation of 2-pyridylindoles and 2-pyridylpyrroles has been reported: a) R. P. Thummel, V. Hedge, *J. Org. Chem.* **1989**, *54*, 1720–1725; b) F. Wu, C. M. Chamchoumis, R. P. Thummel, *Inorg. Chem.* **2000**, *39*, 584–590.
- [9] For a review on potent small organic inhibitors of GSK-3, see a) A. Martinez, A. Castro, I. Dorronsoro, M. Alonso, *Med. Res. Rev.* **2002**, *22*, 373–384.
- [10] L. Meijer, A.-L. Skaltsounis, P. Magiatis, P. Polychronopoulos, M. Knockaert, M. Leost, X. P. Ryan, C. A. Vonica, A. Brivanlou, R. Dajani, C. Crovace, C. Tarricone, A. Musacchio, S. M. Roe, L. Pearl, P. Greengard, *Chem. Biol.* **2003**, *10*, 1255–1266.
- [11] J. Witherington, V. Bordas, A. Gaiba, A. Naylor, A. D. Rawlings, B. P. Slingsby, D. G. Smith, A. K. Takle, R. W. Ward, *Bioorg. Med. Chem. Lett.* **2003**, *13*, 3059–3062.
- [12] C. Kunick, K. Lauenroth, M. Leost, L. Meijer, T. Lemcke, *Bioorg. Med. Chem. Lett.* **2004**, *14*, 413–416.
- [13] a) P. J. Morin, *BioEssays* **1999**, *21*, 1021–1030; b) P. Cohen, S. Frame, *Nat. Rev. Mol. Cell Biol.* **2001**, *2*, 769–776; c) R. S. Jope, G. V. W. Johnson, *Trends Biochem. Sci.* **2004**, *29*, 95–102.
- [14] F. Zhang, C. J. Phiel, L. Spece, N. Gurvich, P. S. Klein, *J. Biol. Chem.* **2003**, *278*, 33067–33077.
- [15] P. S. Klein, D. A. Melton, *Proc. Natl. Acad. Sci. USA* **1996**, *93*, 8455–8459.
- [16] J. Heasman, *Development* **1997**, *124*, 4179–4191.
- [17] W. B. Busa, R. L. Gimlich, *Dev. Biol.* **1989**, *132*, 315–324.